Fentanyl Buccal Tablet for Breakthrough Cancer Pain: Why Titrate?

Pain Practice

Volumn 11, Issue 2, 2011, Pages 185-190

  Kleeberg, Ulrich R ^a   Filbet, Marilène ^b   Zeppetella, Giovambattista ^c  

^a Hämatologisch Onkologische Praxis Altona HOPA   (Germany)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c St Clare Hospice   (United Kingdom)

Author keywords

Breakthrough cancer pain; Rapid onset opioid; Titration

Indexed keywords

FENTANYL; OPIATE DERIVATIVE;

CANCER PAIN; COMORBIDITY; DRUG ABSORPTION; DRUG DOSE TITRATION; HUMAN; PATIENT SATISFACTION; PHARMACODYNAMICS; REVIEW; TABLET;

EID: 79952308234     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2010.00414.x     Document Type: Review

References (32)

1. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273-281.
2. Mercadante S, Radbruch L, Caraceni A, etal. Steering Committee of the European Association for Palliative Care (EAPC) Research Network. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer. 2002;94:832-839.
3. Svendsen KB, Andersen S, Arnason S, etal. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain. 2005;9:195-206.
4. Caraceni A, Martini C, Zecca E, etal. Working Group of an IASP Task Force on Cancer Pain. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18:177-183.
5. Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331-338.
6. Bennett DS, Burton AW, Fishman S, etal. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 1 Assessment. Pharm Ther. 2005;30:296-301.
7. Zeppetella G, Ribeiro MD. Pharmacotherapy of cancer-related episodic pain. Expert Opin Pharmacother. 2003;4:493-502.
8. Patt RB, Ellison NM. Breakthrough pain in cancer patients: characteristics, prevalence, and treatment. Oncology. (Williston Park). 1998;12:1035-1046. discussion 1049-1052.
9. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129-134.
10. Bennett DS, Burton AW, Fishman S, etal. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2 Management. Pharm Ther. 2005;30:354-361.
11. Hanks GW, de Conno F, Cherny N, etal. Morphine and the alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84:587-593.
12. Blick SK, Wagstaff AJ. Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer. Drugs. 2006;66:2387-2393. discussion 2394-2395.
13. Mystakidou K, Katsouda E, Parpa E, Tsiatas ML, Vlahos L. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics. J Opioid Manag. 2005;1:36-40.
14. Durfee S, Messina J, Khankari RK. Fentanyl effervescent buccal tablets: enhanced buccal absorption. Am J Drug Deliv. 2006;4:1-5.
15. Lossignol DA, Dumitrescu C. Breakthrough pain: progress in management. Curr Opin Oncol. 2010;22:302-306.
16. Pather SI, Siebert JM, Hontz J, Khankari RK, Gupte SV, Kumbale R. Enhanced buccal delivery of fentanyl using the OraVescent drug delivery system. Drug Deliv Technol. 2001;1:54-57.
17. Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol. 2007;5:327-334.
18. Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22:805-811.
19. Coluzzi PH, Schwartzberg L, Conroy JD, etal. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001;91:123-130.
20. Portenoy RK, Payne R, Coluzzi P, etal. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain. 1999;79:303-312.
21. Rauck RL, Tark M, Reyes E, etal. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009;25:2877-2885.
22. Rauck R, North J, Gever LN, Tagarro I, Finn AL. Fentanyl buccal solid film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol. 2009;21:1308-1314.
23. Mercadante S, Radbruch L, Davies A, etal. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised crossover trial. Curr Med Res Opin. 2009;25:2805-2815.
24. Friedrich C, Kolb G, Wedding U, Pientka L. Comprehensive geriatric assessment in the elderly cancer patient. Onkologie. 2003;26:355-360.
25. Dahan A, Kest B, Waxman AR, Sarton E. Sex-specific responses to opiates: animal and human studies. Anesth Analg. 2008;107:83-95.
26. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348:529-537.
27. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352:2211-2221.
28. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin or their combination for neuropathic pain. N Engl J Med. 2005;352:1324-1334.
29. Zeppetella G. Fentanyl buccal tablet: a breakthrough in BTcP treatment. Eur J Palliat Care. 2009;16(Suppl):13-17.
30. ® Summary of Product Characteristics. Feruary 2010.
31. Weinstein SM, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study. Cancer. 2009;115:2571-2579.
32. American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 5th ed. Glenview, III: American Pain Society; 2007.